SMDAM
ALXN

Sumitomo Mitsui DS Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sumitomo Mitsui DS Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,841
Closed -$2.54M – 768
2021
Q2 		$2.54M Sell
13,841
-107
-0.8% -$18.4K 0.06% 277
2021
Q1 		$2.13M Buy
13,948
+31
+0.2% +$4.79K 0.06% 296
2020
Q4 		$2.17M Sell
13,917
-29
-0.2% -$3.73K 0.06% 275
2020
Q3 		$1.59M Buy
13,946
+222
+2% +$23.9K 0.05% 307
2020
Q2 		$1.54M Buy
13,724
+730
+6% +$77.5K 0.05% 292
2020
Q1 		$1.17M Sell
12,994
-822
-6% -$80.7K 0.05% 314
2019
Q4 		$1.49M Sell
13,816
-44
-0.3% -$4.71K 0.05% 321
2019
Q3 		$1.36M Buy
13,860
+1,927
+16% +$217K 0.05% 327
2019
Q2 		$1.56M Sell
11,933
-3,349
-22% -$432K 0.06% 277
2019
Q1 		$2.06M Buy
15,282
+714
+5% +$88.8K 0.03% 350
2018
Q4 		$1.42M Sell
14,568
-829
-5% -$98K 0.03% 382
2018
Q3 		$2.14M Sell
15,397
-117
-0.8% -$14.7K 0.03% 347
2018
Q2 		$1.93M Buy
15,514
+230
+2% +$26.9K 0.03% 366
2018
Q1 		$1.7M Sell
15,284
-993
-6% -$119K 0.03% 398
2017
Q4 		$1.95M Sell
16,277
-1,045
-6% -$127K 0.03% 372
2017
Q3 		$2.43M Sell
17,322
-685
-4% -$93.1K 0.04% 309
2017
Q2 		$2.19M Sell
18,007
-852
-5% -$99.2K 0.04% 330
2017
Q1 		$2.29M Buy
18,859
+1,849
+11% +$238K 0.04% 319
2016
Q4 		$2.08M Sell
17,010
-186
-1% -$22.8K 0.04% 313
2016
Q3 		$2.11M Sell
17,196
-45
-0.3% -$5.79K 0.05% 300
2016
Q2 		$2.01M Buy
17,241
+232
+1% +$32.9K 0.06% 264
2016
Q1 		$2.37M Buy
17,009
+542
+3% +$79.6K 0.07% 232
2015
Q4 		$3.14M Sell
16,467
-366
-2% -$63.9K 0.11% 191
2015
Q3 		$2.63M Buy
16,833
+1,236
+8% +$225K 0.09% 211
2015
Q2 		$2.82M Sell
15,597
-132
-0.8% -$22.8K 0.09% 221
2015
Q1 		$2.73M Sell
15,729
-1,171
-7% -$212K 0.08% 231
2014
Q4 		$3.13M Sell
16,900
-1,504
-8% -$279K 0.1% 209
2014
Q3 		$3.05M Sell
18,404
-1,088
-6% -$179K 0.09% 218
2014
Q2 		$3.04M Sell
19,492
-1,073
-5% -$169K 0.09% 236
2014
Q1 		$3.13M Sell
20,565
-1,348
-6% -$214K 0.09% 209
2013
Q4 		$2.92M Sell
21,913
-1,505
-6% -$181K 0.08% 221
2013
Q3 		$2.72M Sell
23,418
-1,231
-5% -$135K 0.08% 232
2013
Q2 		$2.27M Buy
+24,649
New +$2.38M 0.06% 269

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management's ALXN Position: Q3 2021 in Review

Sumitomo Mitsui DS Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 13,841 shares — an estimated $2.54M sold.

Sumitomo Mitsui DS Asset Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $3.14M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Sumitomo Mitsui DS Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sumitomo Mitsui DS Asset Management sold 13,841 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.54M.
  • Sumitomo Mitsui DS Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Sumitomo Mitsui DS Asset Management's Alexion Pharmaceuticals position peaked at $3.14M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q3 2021, filed 15 Oct 2021.